Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone44-12-3543-0000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$59.51 million
Profitability
Miscellaneous
Employees406
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions
What is Adaptimmune Therapeutics' stock symbol?
Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."
How were Adaptimmune Therapeutics' earnings last quarter?
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) posted its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.07. The biotechnology company had revenue of $0.16 million for the quarter, compared to analyst estimates of $4.25 million. View Adaptimmune Therapeutics' Earnings History.
When is Adaptimmune Therapeutics' next earnings date?
What price target have analysts set for ADAP?
8 Wall Street analysts have issued 1 year price objectives for Adaptimmune Therapeutics' stock. Their forecasts range from $4.15 to $12.00. On average, they expect Adaptimmune Therapeutics' stock price to reach $7.03 in the next twelve months. This suggests a possible upside of 604.6% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.
What is the consensus analysts' recommendation for Adaptimmune Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.
Has Adaptimmune Therapeutics been receiving favorable news coverage?
News articles about ADAP stock have been trending negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a daily sentiment score of -2.5 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Adaptimmune Therapeutics.
Who are some of Adaptimmune Therapeutics' key competitors?
Some companies that are related to Adaptimmune Therapeutics include Tcr2 Therapeutics (TCRR), Prevail Therapeutics (PRVL), Agenus (AGEN), CASI Pharmaceuticals (CASI), Avrobio (AVRO), Precision BioSciences (DTIL), Harpoon Therapeutics (HARP), Gritstone Oncology (GRTS), Cellular Biomedicine Group (CBMG), ADMA Biologics (ADMA), PDL BioPharma (PDLI), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), Eiger Biopharmaceuticals (EIGR) and Sutro Biopharma (STRO).
What other stocks do shareholders of Adaptimmune Therapeutics own?
Who are Adaptimmune Therapeutics' key executives?
Adaptimmune Therapeutics' management team includes the folowing people:
- Mr. James Julian Noble, CEO & Director (Age 60)
- Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 52)
- Mr. Adrian Rawcliffe, Chief Financial Officer (Age 47)
- Mr. William C. Bertrand Jr., Chief Operating Officer (Age 54)
- Dr. Rafael Amado, Pres of R&D (Age 55)
When did Adaptimmune Therapeutics IPO?
(ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
How do I buy shares of Adaptimmune Therapeutics?
Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Adaptimmune Therapeutics' stock price today?
One share of ADAP stock can currently be purchased for approximately $1.00.
How big of a company is Adaptimmune Therapeutics?
Adaptimmune Therapeutics has a market capitalization of $104.38 million and generates $59.51 million in revenue each year. The biotechnology company earns $-95,510,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.View Additional Information About Adaptimmune Therapeutics.
What is Adaptimmune Therapeutics' official website?
How can I contact Adaptimmune Therapeutics?
Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]
MarketBeat Community Rating for Adaptimmune Therapeutics (NASDAQ ADAP)
MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote "Outperform" if you believe ADAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
